Hanmi registered patent for a new modified anti-obesity drug.

Published: 2006-02-15 06:57:00

Updated: 2006-02-15 06:57:00

Hanmi announced that a patent on the title of "Pharmaceutical composite of a crystalline hemi-hydrae of Sibutramine methansulfonate" was registered in Korea, by spending about 3.7 billion won for the new modified new Sibutramine derivative, an anti-obesity drug, showing a significant improvement...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK